New Hope for KRAS-Mutant Cancers: Degraders and Inhibitors Emerge
Researchers are developing novel drug strategies, including degraders and inhibitors, to target KRAS protein mutations implicated in various cancers. Historically challenging to treat, these mutations are now the focus of ongoing clinical trials, with initial results being reported and anticipated. These new approaches are expected to be combined with existing or other new therapies to create comprehensive treatment regimens.
Understanding KRAS and Its Challenges in Cancer Therapy
KRAS is a protein belonging to the RAS family, essential for cell growth and proliferation. Specific mutations in the KRAS protein can cause it to remain in an "on" state, leading to the uncontrolled cellular growth characteristic of cancer.
KRAS mutations have historically been difficult targets for drug development, earning the protein a reputation as 'undruggable.'
Previous attempts to develop drugs that inhibit mutant KRAS faced challenges due to the protein's relatively smooth surface, which made drug binding difficult. Even when compounds were identified, resistance frequently developed through mechanisms such as new KRAS mutations or the activation of alternative cellular processes.
Novel Therapeutic Approaches
Current research is exploring two primary drug design strategies to overcome these challenges:
-
Degraders: These compounds are designed to bind to KRAS and then tether it to an E3 ubiquitin ligase. This action chemically marks KRAS for degradation, instructing the cell's waste-processing machinery to break down and remove the protein. This method aims to eliminate the mutant protein entirely rather than merely inhibiting its function.
-
Inhibitors: Another drug is being developed that inhibits multiple mutant forms of KRAS and related proteins. This approach seeks to directly block the function of the problematic KRAS protein.
Clinical Progress
Clinical trials are underway to evaluate these new strategies. A clinical trial for a drug designed to degrade a specific form of mutant KRAS has reported initial results.
In parallel, four large clinical trials are testing an inhibitor drug that targets various mutant forms of KRAS and related proteins. Initial results from one of these studies are expected soon.
Future Outlook for Cancer Treatment
Experts suggest that these individual approaches are unlikely to provide standalone cures for KRAS-mutant cancers.
Instead, the expectation is that they will be combined with each other or with existing cancer treatments to create comprehensive regimens.
This strategy aims to more effectively overcome the resistance mechanisms developed by KRAS-mutant cancers, as noted by Dieter Saur, a gastroenterologist and cancer researcher at the Technical University of Munich.